Clinical Trial Update: Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating NT 201, a botulinum neurotoxin type A formulation free of complexing proteins, for sleep-disordered breathing was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sleep-disordered Breathing

Drugs mentioned

• NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) (Botulinum neurotoxin type A free of complexing proteins)

Snippet

Sponsor: Merz Pharmaceuticals GmbH | Conditions: Sleep-Disordered Breathing | Phase 2 | Status: WITHDRAWN